AEArun Elangovan

Arun Elangovan

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Arun Elangovan has a total of 86 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Report from the 26th Annual Western Canadian Gastrointestinal Cancer Consensus Conference on Hepatocellular and Biliary Tract Cancer, Saskatoon, Saskatchewan, 17–18 October 2024

    by Deepti Ravi, Shahid Ahmed, Blaire Anderson, Brady Anderson, Bryan Brunet, Haji Chalchal, Arun Elangovan, Georgia Geller, Vallerie Gordon, Branawan Gowrishankar, et al.

    The 26th annual Western Canadian Gastrointestinal Cancer Consensus Conference (WCGCCC) was held in Saskatoon, Saskatchewan, on 17–18 October 2024. The WCGCCC is an interactive multidisciplinary conference that was attended by healthcare professionals from across Western Canada (British Columbia, Alberta, Saskatchewan, and Manitoba) who are involved in the care of patients with hepatocellular and biliary tract cancers. Specialists from the fields of medical and radiation oncology, interventional radiology, pathology and laboratory medicine, and general and hepatobiliary surgery participated in presentations and discussions for the purpose of developing the recommendations presented here. This consensus statement addresses current issues in the management of hepatocellular and biliary tract cancers.


  • Open Access

    Quantifying Intra- and Inter-Observer Variabilities in Manual Contours for Radiotherapy: Evaluation of an MR Tumor Autocontouring Algorithm for Liver, Prostate, and Lung Cancer Patients

    by Gawon Han, Arun Elangovan, Jordan Wong, Asmara Waheed, Keith Wachowicz, Nawaid Usmani, Zsolt Gabos, Jihyun Yun, B. Gino Fallone

    Real-time tumor-tracked radiotherapy with a linear accelerator-magnetic resonance (linac-MR) hybrid system requires accurate tumor delineation at a fast MR imaging rate. Various autocontouring methods have been previously evaluated against “gold standard” manual contours by experts. However, manually drawn contours have inherent intra- and inter-observer variations. We aim to quantify these variations and evaluate our tumor-autocontouring algorithm against the manual contours. Ten liver, ten prostate, and ten lung cancer patients were scanned using a 3 tesla (T) magnetic resonance imaging (MRI) scanner with a 2D balanced steady-state free precession (bSSFP) sequence at 4 frames/s. Three experts manually contoured the tumor in two sessions. For autocontouring, an in-house built U-Net-based autocontouring algorithm was used, whose hyperparameters were optimized for each patient, expert, and session (PES). For evaluation, (A) Automatic vs. Manual and (B) Manual vs. Manual contour comparisons were performed. For (A) and (B), three types of comparisons were performed: (a) same expert same session, (b) same expert different session, and (c) different experts, using Dice coefficient (DC), centroid displacement (CD), and the Hausdorff distance (HD). For (A), the algorithm was trained using one expert’s contours and its autocontours were compared to contours from (a)–(c). For Automatic vs. Manual evaluations (Aa–Ac), DC = 0.91, 0.86, 0.78, CD = 1.3, 1.8, 2.7 mm, and HD = 3.1, 4.6, 7.0 mm averaged over 30 patients were achieved, respectively. For Manual vs. Manual evaluations (Ba–Bc), DC = 1.00, 0.85, 0.77, CD = 0.0, 2.1, 2.8 mm, and HD = 0.0, 4.9, 7.2 mm were achieved, respectively. We have quantified the intra- and inter-observer variations in manual contouring of liver, prostate, and lung patients. Our PES-specific optimized algorithm generated autocontours with agreement levels comparable to these manual variations, but with high efficiency (54 ms/autocontour vs. 9 s/manual contour).

  • Open Access

    Patient-Specific Hyperparameter Optimization of a Deep Learning-Based Tumor Autocontouring Algorithm on 2D Liver, Prostate, and Lung Cine MR Images: A Pilot Study

    by Gawon Han, Keith Wachowicz, Nawaid Usmani, Don Yee, Jordan Wong, Arun Elangovan, Jihyun Yun, B. Gino Fallone

    Linear accelerator–magnetic resonance (linac-MR) hybrid systems allow for real-time magnetic resonance imaging (MRI)-guided radiotherapy for more accurate dose delivery to the tumor and improved sparing of the adjacent healthy tissues. However, for real-time tumor detection, it is unfeasible for a human expert to manually contour (gold standard) the tumor at the fast imaging rate of a linac-MR. This study aims to develop a neural network-based tumor autocontouring algorithm with patient-specific hyperparameter optimization (HPO) and to validate its contouring accuracy using in vivo MR images of cancer patients. Two-dimensional (2D) intrafractional MR images were acquired at 4 frames/s using 3 tesla (T) MRI from 11 liver, 24 prostate, and 12 lung cancer patients. A U-Net architecture was applied for tumor autocontouring and was further enhanced by implementing HPO using the Covariance Matrix Adaptation Evolution Strategy. Six hyperparameters were optimized for each patient, for which intrafractional images and experts’ manual contours were input into the algorithm to find the optimal set of hyperparameters. For evaluation, Dice’s coefficient (DC), centroid displacement (CD), and Hausdorff distance (HD) were computed between the manual contours and autocontours. The performance of the algorithm was benchmarked against two standardized autosegmentation methods: non-optimized U-Net and nnU-Net. For the proposed algorithm, the mean (standard deviation) DC, CD, and HD of the 47 patients were 0.92 (0.04), 1.35 (1.03), and 3.63 (2.17) mm, respectively. Compared to the two benchmarking autosegmentation methods, the proposed algorithm achieved the best overall performance in terms of contouring accuracy and speed. This work presents the first tumor autocontouring algorithm applicable to the intrafractional MR images of liver and prostate cancer patients for real-time tumor-tracked radiotherapy. The proposed algorithm performs patient-specific HPO, enabling accurate tumor delineation comparable to that of experts.


  • Impact of Immunohistochemical profiling of Glioblastoma multiforme on clinical outcomes: Real-world scenario in resource limited setting

    by Narendra Kumar, Arun Elangovan, Renu Madan, ChinnaBabu Dracham, Divya Khosla, Manjul Tripathi, Kirti Gupta, Rakesh Kapoor


  • Expanding role of radiotherapy in adenoid cystic carcinoma of the tracheobronchial tree: a new horizon

    by ChinnaBabu Dracham, Divya Khosla, Rakesh Kapoor, Treshita Dey, Kannan Periasamy, Arun Elangovan, Renu Madan, Shikha Goyal, Narendra Kumar

    Primary adenoid cystic carcinomas (ACCs) of central trachea-bronchi system are rare and heterogeneous tumors. Definitive radiotherapy (RT) is the recommended treatment in surgically unresectable or incomplete resection or in the presence of severe comorbidities. To evaluate the clinical features and outcomes of patients with ACC of trachea-bronchi treated with radiotherapy. Retrospective medical records review was done in all patients with histologically confirmed ACC of trachea-bronchi between January 2010 and December 2019. Patient disease and treatment characteristics and toxicity data were analyzed. Overall survival (OS), local recurrence-free survival (LRFS), and distant metastasis-free survival (DMFS) were computed using Kaplan-Meier method (log-rank test). Nineteen patients (10 women and 9 men) were included in this analysis with median age of 40 years (range, 14–70). Of these patients, 63.2% (n = 12) presented in stage IV disease. Twelve and three patients received definitive (median dose 67.8 Gy) and adjuvant (median dose 50 Gy) RT, respectively. The median follow-up was 42.5 months (range, 4–120); 15 patients were alive and 4 were dead at that time. Local recurrence or progression was observed in 52.6% and distant metastasis found in 47.3% of patients. The 5-year OS, LRFS, and DMFS for all patients were 81.2%, 52.8%, and 39.6%, respectively. Baseline lymph node involvement showed significant impact on OS (56.3% vs 100%, p = 0.011). Among patients receiving definitive RT, patients with higher RT dose (⩾66 Gy) had significantly better survival outcomes (5-year LRFS: 75% vs 16.7%, p = 0.013). Definitive RT is an exemplary treatment for unresectable disease. Higher dose is recommended to improve long-term outcomes.


  • Multimodality treatment for Central Nervous System Germ Cell Tumors: Disease spectrum and management strategies - A tertiary care center experience from India

    by Narendra Kumar, Renu Madan, Chinna Babu Dracham, Divya Khosla, Namrata Das, Treshita Dey, Arun Elangovan, Manjul Tripathi, Kirti Gupta, Chirag K. Ahuja, et al.


  • Open Access

    Prognostic Value of HPV Infection Assessed by p16 Immunohistochemistry and the Influence of Tobacco Usage in Oropharyngeal Cancers: Real World Scenario

    by Sushmita Ghoshal, Chinna Babu Dracham, Archana Sundaram, Rajesh Kumar, Amanjit Bal, Ashim Das, Amit Bahl, Roshan Kumar Verma, Arun Elangovan

    To find if an association could be established between Human Papilloma Virus (HPV) infection and oropharyngeal cancers (OPCs) in a group of patients known to be regular users of tobacco, and to determine the impact of HPV status on clinical outcomes.Case records of 212 patients with AJCC-7 (The American Joint Committee on Cancer 7th edition) stages II–IVB non metastatic squamous cell carcinoma of the oropharynx treated using radical radiotherapy with or without chemotherapy during the years 2015–2018 were retrieved. Formalin-fixed, paraffin-embedded blocks from oropharyngeal biopsies were available for 177 patients and were evaluated for p16 expression by immunohistochemical (IHC) staining. More than 50% nuclear staining with or without cytoplasmic staining was considered HPV+ . The association between tobacco use and HPV, as well as the influence of HPV status on survival outcomes were assessed. p16 expression was found to be positive in 23(13%) patients. Significant association was found between chewable tobacco usage and HPV positivity (p = 0.051). The median follow up was 20.5 months (range: 3–80). 5-year Overall Survival was 43.4% and 29.8% (p = 0.044) in HPV+ and HPV− patients, respectively. Local control was significantly better in HPV+ patients (38.6% vs. 25.3%, p = 0.049). There was also a trend towards improved Disease-free Survival in HPV+ patients (31 months vs. 15 months, p = 0.078). Though less in prevalence among the Indian population, improved outcomes in HPV+ OPC patients and widely available IHC HPV assays signifies the routine implementation of p16 testing in day-to-day clinical practice.


  • Quality of Life Among Ovarian Cancer Survivors: A Tertiary Care Center Experience from India

    by Renu Madan, Chinna Babu Dracham, Arun Elangovan, Bhavana Rai, G. Y. Srinivasa, Ankita Gupta, Divyesh Kumar, Sushmita Ghoshal


  • Open Access

    Implementation of high-dose-rate brachytherapy for prostatic carcinoma in an unshielded operating room facility

    by Arun Elangovan, Siraj Husain, Philip McGeahy, Michael Roumeliotis, Che Hsuan David Wu, Nathan Wolfe, Tyler Meyer, Elizabeth Watt, Kevin Martell, Kundan Thind


  • Open Access

    Primary Transitional Cell Carcinoma of Fallopian Tube: A Rare Entity with Review of Literature

    by Arun Elangovan, Chinna Babu Dracham, Lokeswari Annam, Vani Bharani

    Objective: Primary fallopian tube carcinoma (PFTC) is a rare entity constituting only 0.2-1.5% of all primary female genital-tract malignancies. Transitional cell carcinoma of fallopian tube is very rare constituting only around 10% of the PFTC and very less literature have been reported worldwide. Case report: A 59-year-old postmenopausal women presented with discharge per vaginum and abdominal distension, and was found to have right adnexal mass on clinical examination. Imaging findings were suggestive of a heterogenous adnexal mass and she underwent staging laparotomy. Post-operative histopathology examination confirmed a primary transitional cell carcinoma of right fallopian tube. FIGO stage was IA, and she received six cycles of adjuvant chemotherapy. The patient is now alive, after 10-years of initial treatment.